Skip to content
Tenfell
Awarded contract
Published 22 Sep 2026

Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service

NHS England · London

Key facts

Contract value
£26,143,000
Awarded
23 Aug 2026
Procedure
Open procedure
Buyer type
Central government

Awarded to 16 suppliers

SupplierValue
Northern Care Alliance NHS Foundation Trust£1,036,000
University Hospitals Bristol and Weston NHS Foundation Trust£1,036,000
Sheffield Teaching Hospitals NHS Foundation Trust£1,036,000
Oxford University Hospitals NHS Foundation Trust£1,036,000
The Newcastle upon Tyne Hospitals NHS Foundation Trust£1,036,000
University Hospitals Southampton£1,036,000
University College London Hospitals NHS Foundation Trust£1,036,000
St George's University Hospitals NHS Foundation Trust£1,036,000
King's College Hospital NHS Foundation Trust£1,036,000
Great Ormond Street Hospital£776,000
Guy's and St Thomas' NHS Foundation Trust£776,000
University Hospitals of North Staffordshire NHS Trust£776,000
Sheffield Children's NHS Foundation Trust£776,000
Leeds Teaching Hospitals NHS Trust£776,000
North Manchester General Hospital£776,000
Alder Hey Children's NHS Foundation Trust£776,000

Description

Intention to award the Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service.

This is a a one-time, in vivo gene replacement therapy, for use in babies aged 12 months and under, that utilises an adeno-associated virus serotype 9 (AAV9) vector, modified to contain a functional copy of the human SMN1 gene. It is administered intravenously, allowing the vector to deliver the gene into motor neurones and peripheral tissues, enabling the sustained expression of survival motor neuron (SMN) protein, which is deficient or mutated in individuals with SMA.

Onasemnogene abeparvovec intrathecal (OAV101 IT) is a one-time in vivo gene replacement therapy for patients with SMA, proposed to treat individuals with SMA aged 2 years and over. This intrathecal injection will be used to treat a distinct cohort of SMA patients to Zolgensma. It will be assessed via NICE’s technology appraisal programme, with an expected final guidance publication date in late 2026.

Procurement was carried out in Lots for the services as detailed above. Contract values are estimated and will be dependent on number of patients actually treated at each awarded provider.

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Find a Tender (Open Government Licence v3.0). Always read the original notice before responding.